LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL), a biopharmaceutical company developing innovative drugs to treat type 2 diabetes, today announced that the Company will present full data analysis of a Phase 2b trial for their drug candidate Imeglimin at the upcoming American Diabetes Association (ADA) 75th Scientific Sessions in Boston, MA, on Saturday, June 6 and Sunday, June 7.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
